Do you ever notice that you feel more energized or alert when meeting new people and forming first impressions? Other times, a first meeting will rub you the wrong way and you may feel less attentive. If you've experienced one or both of these, you may wonder: What makes a good first impression? How do you know you want to become friends with someone? What information do we pay attention to when interacting with someone for the first time? Good questions! Neuroscience and psychology researchers wonder about the same things. Here at the Social Neuroscience and Health lab, we study how the brain and the immune system work together to influence our behaviors and experiences. The Friendship Pathways Study is a research project aiming to answer questions about how the brain and immune system communicate when meeting new people and forming friendships.

The research study is testing a new study treatment for peanut allergy. The new study treatment is called PVX108. The study doctor and the study sponsor want to learn more about this study drug and to see if it is safe and helpful for children who are allergic to peanuts. The study drug has been used safely in adults and teenagers with peanut allergy. This will be the first time that the study drug will be tested on children in this age group.

In this study, we want to learn if there is a relationship between proficiency in a language and how a person reads and depends on certain word structure cues.

Did your spouse or partner deploy with the 82nd Airborne during an IRF activation? Were any of your children in grades K-12 during that time? If so, we would like to hear from you about your experiences! Your voice matters.

Have you been diagnosed with Lateralized Oropharyngeal Cancer . If so, you may be able to take part in a research study looking at the safety by using a special imaging study called lymph node mapping (lymphatic mapping) Single Photon Emission Computed Tomography (SPECT-CT) compared to the usual treatment when radiotherapy is given .

Cyclophosphamide is a chemotherapy (chemo) drug often given after a transplant to prevent GvHD. We are doing this study to see if a lower dose of cyclophosphamide after transplant is safer, but just as effective. Cyclophosphamide can prevent GvHD, but it can also make you sick and more likely to get an infection. This study will look at how well a lower dose of cyclophosphamide works to reduce these side effects, while also preventing GvHD. This study does not include any new or untested drugs. The drugs and procedures in this study are standard for transplant.

We are testing out a device that collects physical function data among older adults who have multiple chronic conditions. We want to see if the device works efficiently and is user friendly.

The study treatment, finerenone, is being developed to help people who have long lasting kidney disease, also known as chronic kidney disease (CKD). It works by blocking a certain hormone called aldosterone that causes injury and inflammation in the heart and kidney which is known to play a role in CKD. In this study, the researchers want to learn if finerenone works the same way in kidney transplant recipients. Some subjects will receive the study drug and some will receive a placebo.

Do you have Leukemia, Lymphoma or any other blood disorder that requires you to have frequent visits to have laboratory tests? You maybe able to participate in a study using a device to help monitor your abnormal blood levels.

In this study, we want to better understand how experiences of stigma and discrimination affect HIV testing and PrEP use among young Latino sexual minority men.